Document is current

Article History

Received: 15 March 2024

Accepted: 10 May 2024

First Online: 6 July 2024

Declarations

:

: All members involved in creating the guidelines submitted conflict of interest statements based on the rules of the academic society. The specific conflict of interest statements are as follows: Employment: Wataru Asakura, Office of New Drug I, Pharmaceuticals and Medical Devices Agency (PMDA), Tokyo, Japan; Yoshitaka Isaka, Department of Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan; Kunitoshi Iseki, Clinical Research Support Center, Tomishiro Central Hospital, Okinawa, Japan; Kohjiro Ueki, Diabetes Research Center, National Center for Global Health and Medicine, Tokyo, Japan; Tomoko Usui, Division of Nephrology and Endocrinology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan; Hirokazu Okada, Department of Nephrology, Saitama Medical University, Saitama, Japan; Naoki Kashihara, Department of Nephrology and Hypertension, Kawasaki Medical School, Okayama, Japan; Eiichiro Kanda, Medical Science, Kawasaki Medical School, Okayama, Japan; Masaomi Nangaku, Division of Nephrology and Endocrinology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan; Kunihiro Matsushita, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Maryland, USA; Hirotaka Watada, Department of Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan. Consultancies: All the authors, None. Honoraria: Wataru Asakura, Yoshitaka Isaka, Kunitoshi Iseki, Seiji Itano, Tomoko Usui, Eiichiro Kanda, Yuka Sugawara, Mototsugu Tanaka, Koji Tomori, Kunihiro Matsushita, and Yusuke Watanabe, None. Kohjiro Ueki, Sumitomo Pharma Co., Ltd., Novo Nordisk Pharma Ltd., Takeda Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Abbott Japan LLC, Bayer Yakuhin, Ltd, Kowa Company, Ltd, Nippon Boehringer Ingelheim Co., Ltd., Daiichi Sankyo Ltd.; Hirokazu Okada, Daiichi Sankyo Ltd., AstraZeneca K.K., Mitsubishi Tanabe Pharma Corporation, ONO PHARMACEUTICAL CO., LTD., Nippon Boehringer Ingelheim Co., Ltd., Astellas Pharma Inc., Kyowa Kirin Co., Ltd., Bayer Yakuhin, Ltd, Torii Pharmaceutical Co.,Ltd; Naoki Kashihara, Daiichi Sankyo Ltd., AstraZeneca K.K., Mitsubishi Tanabe Pharma Corporation, ONO PHARMACEUTICAL CO., LTD., Nippon Boehringer Ingelheim Co., Ltd., Astellas Pharma Inc., Kyowa Kirin Co., Ltd., Bayer Yakuhin, Ltd, Nobelpharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Novartis Pharma K.K., Yusuke Suzuki, Kyowa Kirin Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Novartis Pharma K.K., Daiichi Sankyo Ltd., Otsuka Pharmaceutical Co., Ltd., Otsuka America Pharmaceutical, Inc.; Masaomi Nangaku, Kyowa Kirin Co., Ltd., Astellas Pharma Inc., Mitsubishi Tanabe Pharma Corporation, Bayer Yakuhin, Ltd, Japan Tobacco Inc.; Rimei Nishimura, Eli Lilly Japan K.K., Kissei Pharmaceutical Co., Ltd., Novo Nordisk Pharma Ltd., MEDTRONIC JAPAN CO., LTD., ONO PHARMACEUTICAL CO., LTD., Mitsubishi Tanabe Pharma Corporation, Sanofi K.K., Nippon Boehringer Ingelheim Co., Ltd., Astellas Pharma Inc., Abbott Japan LLC; Takayuki Hamano, Astellas Pharma Inc., Torii Pharmaceutical Co.,Ltd., Kyowa Kirin Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Otsuka Pharmaceutical Co., Ltd., ONO PHARMACEUTICAL CO., LTD.; Kei Fukami, AstraZeneca K.K., Otsuka Pharmaceutical Co., Ltd., Nobelpharma Co., Ltd., ONO PHARMACEUTICAL CO., LTD., Bayer Yakuhin, Ltd, Kyowa Kirin Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Sumitomo Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corporation; Jun Wada, AstraZeneca K.K., Mitsubishi Tanabe Pharma Corporation; Hirotaka Watada, Mitsubishi Tanabe Pharma Corporation, Taisho Pharmaceutical Co., Ltd., Novo Nordisk Pharma Ltd., Astellas Pharma Inc., Abbott Japan LLC, MSD K.K., Kissei Pharmaceutical Co., Ltd., AstraZeneca K.K., ONO PHARMACEUTICAL CO., LTD., Sanofi K.K, Sumitomo Pharma Co., Ltd, Eli Lilly Japan K.K., Nippon Boehringer Ingelheim Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Takeda Pharmaceutical Co., Ltd., Kowa Company, Ltd, Kyowa Kirin Co., Ltd., Terumo Corporation. Stock ownership or options: All the authors, None. Grants received: Wataru Asakura, Yoshitaka Isaka, Kunitoshi Iseki, Seiji Itano, Tomoko Usui, Eiichiro Kanda, Yuka Sugawara, Mototsugu Tanaka, Koji Tomori, Rimei Nishimura, Kei Fukami, Jun Wada, and Yusuke Watanabe, None. Kohjiro Ueki, Nippon Boehringer Ingelheim Co., Ltd., Sumitomo Pharma Co., Ltd, Eli Lilly Japan K.K.; Hirokazu Okada, Kyowa Kirin Co., Ltd., Torii Pharmaceutical Co.,Ltd, Kissei Pharmaceutical Co., Ltd.; Naoki Kashihara, AstraZeneca K.K., Nobelpharma Co., Ltd., Daiichi Sankyo Ltd., Bayer Yakuhin, Ltd.; Yusuke Suzuki, Travere Therapeutics, Inc., Chinook Therapeutics U.S., Inc., Moderna TX, ARGENX IIP BV, Aurinia Pharmaceuticals Inc., Kyowa Kirin Co., Ltd.; Masaomi Nangaku, EPS Corporation, Parexel International Inc., Japan Tobacco Inc.; Takayuki Hamano, Astellas Pharma Inc., Torii Pharmaceutical Co.,Ltd.; Kunitoshi Matsushita, Kyowa Kirin Co., Ltd., Akebia, Kowa Company; Hirotaka Watada, Sanofi K.K., Kowa Company, Ltd, Nippon Boehringer Ingelheim Co., Ltd., Mitsubishi Tanabe Pharma Corporation, ONO PHARMACEUTICAL CO., LTD., MSD K.K., Sanwa Kagaku Kenkyusho Co., Ltd., Sumitomo Pharma Co., Ltd, Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Soiken Holdings Inc.